Posted Feb. 24, 2012 at 6:45 a.m.
FDA
Research Triangle Park, N.C. — The 7-4 vote with one abstention and one "non-vote" from the independent panel does not bind the FDA to rule one way or another on the drug. But the vote of confidence in the compound does run counter to the conclusion of the FDA's own staffers, who were concerned about Northera's short duration and possible safety issues that arose during clinical trials.Copyright 2013 MedCity. All rights reserved.
FDA panel OKs Charlotte-based Chelsea's Parkinson's drug
Post a comment
Print this blog postE-mail blog post
Share
FDA
Research Triangle Park, N.C. — The 7-4 vote with one abstention and one "non-vote" from the independent panel does not bind the FDA to rule one way or another on the drug. But the vote of confidence in the compound does run counter to the conclusion of the FDA's own staffers, who were concerned about Northera's short duration and possible safety issues that arose during clinical trials.Copyright 2013 MedCity. All rights reserved.
Log in or upgrade to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
Durham's high-tech infrastructure, talent lure Virginia company- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows
- Titans of tech seek to excite UNC, Duke grads about a future beyond themselves
- Triangle politician tries to accelerate crowdfunding; bill passes first hurdle